Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic
Authors:
- Thomas Theo BrehmTBThomas Theo Brehm
- Michelle ThompsonMTMichelle Thompson
- Felix UllrichFUFelix Ullrich
- Dorothee SchwingeDSDorothee Schwinge
- Marylyn M. AddoMAMarylyn M. Addo
- Johannes K. KnoblochJKJohannes K. Knobloch
- Martin AepfelbacherMAMartin Aepfelbacher
- Ansgar W. LohseALAnsgar W. Lohse
- Julian Schulze Zur WieschJWJulian Schulze Zur Wiesch
Open Access
- 25 September 2021
- journal article
- research article
- Published by Elsevier in International Journal of Hygiene and Environmental Health
- Vol. 238, 113851
Abstract
No abstract availableKeywords
All Related Versions
Funding Information
- Universitätsklinikum Hamburg-Eppendorf
This publication has 20 references indexed in Scilit:
- SARS-CoV-2 Infection after Vaccination in Health Care Workers in CaliforniaNew England Journal of Medicine, 2021
- Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2JAMA, 2021
- SARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing AntibodiesViruses, 2021
- Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA VaccineNew England Journal of Medicine, 2021
- Longitudinal follow-up of IgG anti-nucleocapsid antibodies in SARS-CoV-2 infected patients up to eight months after infectionJournal of Clinical Virology, 2021
- Seroprevalence of SARS-CoV-2 antibodies among hospital workers in a German tertiary care center: A sequential follow-up studyInternational Journal of Hygiene and Environmental Health, 2021
- Efficacy and Safety of the mRNA-1273 SARS-CoV-2 VaccineNew England Journal of Medicine, 2021
- Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we needSignal Transduction and Targeted Therapy, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020